Expression of 11β-hydroxysteroid dehydrogenase type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study.
Intratumoral biosynthesis of hormone steroids is thought to play a role in the pathogenesis and development of human breast cancer. There is evidence that glucocorticoids may inhibit the development and progression of breast cancer. 11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 is the enzyme which converts inactive cortisone to active cortisol. In order to study the expression of 11β-HSD type 1 in breast cancer and non-cancerous breast tissue, we have developed specific antibodies to 11β-HSD type 1 and proceeded to localization of the enzyme in 84 specimens of breast carcinoma and adjacent non-malignant tissues by immnohistochemistry. The results were correlated with the expression of androgen receptor, estrogen receptor, progesterone receptor, glucocorticoid receptor and CDC47, a cell division marker, as well as the tumor stage, tumor size, nodal status and menopausal status. The expression of 11β-HSD type 1 in 64% of breast cancer specimens appeared significantly lower than that observed in normal adjacent tissues (97% of cases being positive). There was no significant correlation between 11β-HSD type 1 expression and the clinicopathological parameters studied. The decrease in 11β-HSD type 1 expression in breast cancer as compared to that observed in the adjacent normal tissues may play a role in the development and/or progression of the cancer by modifying the intratumoral levels of glucocorticoids.
Laval University Hospital Research Center, Quebec, QC, Canada.
Lu
L
Lu
Gang
G
Zhao
Van
V
Luu-The
Johanne
J
Ouellet
Zhinmin
Z
Fan
Fernand
F
Labrie
Georges
G
Pelletier
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000378:metabolism*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001940:Breast / Q000378:metabolism* / Q000473:pathology; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D064168:Minichromosome Maintenance Complex Component 7; D009687:Nuclear Proteins / Q000378:metabolism; D011379:Prognosis; D011944:Receptors, Androgen / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
C410798:AR protein, human; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D009687:Nuclear Proteins; D011944:Receptors, Androgen; D011965:Receptors, Glucocorticoid; D011980:Receptors, Progesterone; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; C101624:MCM7 protein, human; D064168:Minichromosome Maintenance Complex Component 7
Neuroscience. 2007 Mar 2;145(1):110-5
17207581
Cancer Biol Ther. 2006 Aug;5(8):933-40
16775428
Cancer Res. 1976 Dec;36(12):4602-9
1000505
Proc R Soc Lond B Biol Sci. 1958 Dec 17;149(936):303-25
13623785
Cancer Res. 1979 Jul;39(7 Pt 1):2422-8
445441
Int J Oncol. 2007 Apr;30(4):947-53
17332934
J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):181-5
17933521
J Pathol. 2006 Jul;209(3):317-27
16639692
Cancer Res. 2008 Sep 15;68(18):7386-93
18794126
Breast Cancer Res. 2008;10(4):R57
18611262
Cancer Res. 1979 May;39(5):1447-54
427788
Mol Endocrinol. 1993 Sep;7(9):1121-32
8247014
Vitam Horm. 1999;57:249-324
10232052
J Steroid Biochem Mol Biol. 2006 Oct;101(2-3):136-44
16930994
Biochem Soc Trans. 1997 May;25(2):583-7
9191160
J Endocrinol. 1997 Oct;155(1):171-80
9390020
BMC Cancer. 2008 Mar 28;8:84
18373855
Mol Cell Endocrinol. 1999 May 25;151(1-2):121-7
10411326
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14924-9
9405715
Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43
15172700
J Cell Physiol. 1995 May;163(2):365-79
7706379
Horm Res. 1977;8(2):107-16
908552